Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ESCulab

Financiado

Cerrado

European Screening Centre Unique Library for Attractive Biology

By bridging an important gap between basic research and drug development, ESCulab will facilitate the translation of fundamental scientific insights into innovative drug starting points. New biological ideas will be collected by c... ver más

30/11/2023

FOUNDATION LYGATUR...

37M€

Presupuesto del proyecto: 37M€

Líder del proyecto

STICHTING LYGATURE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 18 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2023-11-30

IMI2-2017-12-07: European Screening Centre: unique l... Specific Challenge:The translation of novel biological concepts into drug discovery projects critica...

I+D

Cerrada hace 7 años

0% 50% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

18 Participantes

FOUNDATION LYGATURE

1.43M€ | Lider

Taros Chemicals

292.60K€ | Participante

BIOASCENT

6.48M€ | Participante

GRT

1.48M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 59 meses Fecha Inicio: 2018-12-18
Fecha Fin: 2023-11-30

Líder del proyecto

STICHTING LYGATURE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 37M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto By bridging an important gap between basic research and drug development, ESCulab will facilitate the translation of fundamental scientific insights into innovative drug starting points. New biological ideas will be collected by crowdsourcing, novel targets, phenotypes and pathways translated and de-risked by delivering high-quality chemical starting points for drug development. Innovators from EU academics and SMEs are offered access to state-of-the-art industry-grade facilities, drug discovery expertise, and a top-quality, curated library with over 550,000 unique compounds suitable for screening potential drug targets. The ESCulab drug discovery data generated will allow the innovators to build a proposition that is likely to attract investors and/or drug developers and stimulate them to further exploit these findings. Ultimately, this will result in novel medicines – based on basic scientific findings – that will help patients (sooner). ESCulab will achieve this by starting off the shoulders of the European Lead Factory (ELF), where this principle has been successfully implemented. 15 out of the 18 ESCulab consortium members were involved in ELF, thus ensuring maximum benefit from the ELF legacy. ESCulab will expand and enhance ELF by supporting 185 new screens. Important additions include the application of a much larger compound collection for screening, the ability to accommodate the more complex phenotypic screening assays, and the building of a sustainable business model to ensure access to Collaborative Drug Discovery activities beyond the funding period. The delivery of qualified hit lists (QHLs) is the end point for this project, but during the funding period, ESCulab will attract additonal funding for externally paid screens and hit-to-lead projects for organizations such as charities and foundations for long term sustainability of the initiative.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores